Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | October 03, 2014

Nuclear Medicine is the New Personalized Medicine

Photo courtesy of Siemens Healthcare

Remember the race to map the human genome, when the widest international collaboration in history went up against the efforts of a private corporation, Celera? The race ended in a tie in 2001 with near simultaneous publications in Nature (public effort) and Science (Celera) as both public and private sectors served up analyses of about 80 percent of the genome. Unfortunately, the outcome of this Herculean effort did not come close to meeting expectations. 

Mapping the human genome was supposed to unlock the secrets of disease and make possible truly personalized medicine. It was to have explained why some people fall ill while others do not — and how those who become ill could be best treated. It just didn’t work out that way. 

Now more than a decade later, personalized medicine, based on genetic information, is decades more away. Even just understanding the genome still eludes the grasp of researchers.

What did come from those early days of hyperbole was recognition of how badly the public wants personalized medicine. Patients and providers alike are fed up with medicine as an art. They want it to be a science. That is what personalized medicine was supposed to be. And it is now what nuclear medicine aspires to be.

Once hampered by the negative connotations of its first name, nuclear medicine reinvented itself shortly after the turn of the century, rebranding itself as “molecular imaging.” Measurements of radiotracer uptake complement the visualization of metabolic activity, particularly in positron emission tomography/computed tomography (PET/CT). This hybrid is routinely leveraged to calculate the dose of therapeutic radionuclides and to gauge the effect of therapies on malignant tumors. 

If there’s a fly in the ointment, it’s that the promoters of molecular imaging as the harbinger of personalized medicine may be promising too much. We hear about the commitment of companies in this industry to personalized medicine and the latest gizmo or upgraded gadget that makes it real. To their credit, however, they are careful to describe successes within narrow confines, as in the case of peptide receptor radionuclide therapy (PRRT).

PRRT is on the front lines of this new personalized medicine. Its somatostatin analogs, which selectively bind to the cellular receptors in neuroendocrine tumors, carry a gallium radionuclide that simultaneously emits radiation that kills tumors and makes the analogs visible and quantifiable with PET/CT. The end effect of successful and measurable treatment is decreased tumor size, reduced symptoms and even a halt in tumor progression in many patients with neuroendocrine tumors.

Similar results have been achieved in patients with esophageal and lung cancers, as well as diffuse large B-cell lymphoma, using radiotherapeutic compounds complemented by FDG imaging and quantitation with PET/CT. The potential to do the same with even some advanced forms of single-proton emission computed tomography (SPECT)/CT has also been demonstrated.

Anatomically based tools, such as magnetic resonance imaging (MRI) and CT, pale by comparison. Whereas these modalities record the dimensions of a tumor, those dimensions may be inflamed by the cellular debris that comes from successful chemo- or radiotherapy. Not so with molecular imaging, which demonstrates visually and quantitatively, at least in some cases, the presence of viable tumor. Trends in uptake values graphically show changes in tumor metabolism, giving providers an indication of whether and how well therapies are doing.  

To be sure, molecular medicine is not what personalized medicine was supposed to be. But it is a step in the right direction. Perhaps most importantly, it is a step that can — and is — being taken. 

That it does not spring from knowledge gained by mapping the human genome, I could care less.

Related Content

Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Weight-Bearing CT International Study Group Hosts  Scientific Session at AOFAS Conference
News | Computed Tomography (CT) | June 15, 2018
June 15, 2018 —The Weight-Bearing CT International Study Group will host a scientific session on the benefits of weig
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
360 Photos | 360 View Photos | June 14, 2018
This is a 360 degree image from the Canon Aquilion 64-slice...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
American Society of Neuroradiology Honors Peter Chang with Cornelius G. Dyke Memorial Award
News | Neuro Imaging | June 13, 2018
Peter Chang, M.D., current neuroradiology fellow at UCSF and recently recruited co-director of the UCI Center for...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
Overlay Init